• Publications
  • Influence
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
BACKGROUND High-dose chemotherapy followed by autologous bone marrow transplantation is a therapeutic option for patients with chemotherapy-sensitive non-Hodgkin's lymphoma who have relapses. In thisExpand
  • 2,069
  • 97
International staging system for multiple myeloma.
PURPOSE There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification. PATIENTS AND METHODS ClinicalExpand
  • 1,459
  • 87
  • PDF
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
PURPOSE The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. We combined the International Staging System (ISS) withExpand
  • 796
  • 50
  • PDF
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
PURPOSE We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM). PATIENTS AND METHODS In all, 827 eligible patients with newlyExpand
  • 648
  • 43
  • PDF
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth ofExpand
  • 851
  • 41
  • PDF
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
BACKGROUND Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreatedExpand
  • 781
  • 41
  • PDF
International uniform response criteria for multiple myeloma
New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow Transplant/International Bone Marrow Transplant RegistryExpand
  • 1,625
  • 34
  • PDF
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
BACKGROUND This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had received one to three previous therapies. METHODS We randomly assigned 669Expand
  • 1,716
  • 33
  • PDF
High-dose daunorubicin in older patients with acute myeloid leukemia.
BACKGROUND A complete remission is essential for prolonging survival in patients with acute myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the optimal dose isExpand
  • 657
  • 27
  • PDF
International uniform response criteria for multiple myeloma
Correction to: Leukemia (2006) 20, 1467–1473. doi:10.1038/sj.leu.2404284 It has been identified by the authors that there was an error in the author list. The following author was omitted in error. MExpand
  • 655
  • 27